LONDON, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) today announced that management will participate in a fireside chat at the TD Cowen 46th Annual Health Care Conference on Monday, March 2, 2026 at 3:10 p.m. Eastern Time. A live webcast of Kiniksa’s presentation will be accessible through the Investors section of the company’s website at www.kiniksa.com. A replay of the event will also be available on Kiniksa’s website within approximately 48 hours after the ...

Q4 2025 net product revenue for ZORYVE® (roflumilast) was $127.5 million, an 84% increase compared to Q4 2024, and a 29% increase compared to Q3 2025Full year 2025 net product revenue for ZORYVE was $372.1 million, an increase of 123% over the prior yearReported positive topline data for the INTEGUMENT-INFANT Phase 2 trial of ZORYVE cream 0.05% in children ages 3 to 24 months with mild to moderate atopic dermatitis, with a Supplemental New Drug Application (sNDA) submission expected in Q2 2026Announced expa ...

Hedge fund BVF reported a full exit from Protagonist Therapeutics (NASDAQ:PTGX) in its February 17, 2026, SEC filing, selling 2,560,916 shares worth an estimated $170.12 million. What happened According to its SEC filing dated February 17, 2026, BVF fully liquidated its stake in Protagonist Therapeutics (NASDAQ:PTGX), selling 2,560,916 shares. The quarter-end position value decreased by $170.12 million. What else to know BVF sold out of Protagonist Therapeutics. Top holdings after the filing: NASD ...

Clene Inc. Conference Call Summary Company Overview - **Company Name**: Clene Inc. - **Ticker Symbol**: CLNN - **Industry**: Biopharmaceuticals - **Focus**: Improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, particularly ALS (Amyotrophic Lateral Sclerosis) [1] Core Points and Arguments - **Regulatory Engagement**: Clene is actively engaging with the FDA to seek regulatory flexibility for ALS treatments, emphasizing the urgent need for effective therapies in light of recent tragedies involving ALS patients [6][30]. - **Product Description**: The primary product, CNM-Au8, is described as a nanotherapeutic suspension that can cross the blood-brain barrier, aiming to enhance neuronal housekeeping functions [7][8]. - **Biomarker Significance**: Neurofilament levels are highlighted as critical biomarkers for assessing neurodegenerative diseases, particularly ALS. Elevated neurofilament levels correlate with disease progression and shorter survival [9][11]. - **Clinical Trial Results**: Clene's clinical trials have shown a 94% risk reduction in clinical worsening as a secondary endpoint in the HEALEY study. However, the primary endpoint (ALSFRS) was not met [13][14]. - **FDA Feedback**: The FDA has requested additional evidence regarding neurofilament data and its correlation with survival benefits. Clene is preparing to provide this data [25][26]. - **Future Plans**: Clene plans to file a New Drug Application (NDA) by mid-2026, with potential commercialization by early 2027, contingent on FDA approval [29][40]. Financial Overview - **Funding**: Clene raised $6 million at $6.50 per share, with additional tranches of $7 million and $13 million tied to regulatory milestones, ensuring financial stability through key upcoming events [34][35]. - **Cash Runway**: The company has sufficient cash to navigate through critical milestones, including the FDA Type C meeting and NDA filing [33][34]. Upcoming Milestones - **FDA Type C Meeting**: Expected by the end of March 2026, which will determine the next steps for the NDA submission [36][39]. - **NDA Filing**: Anticipated by the end of the second quarter of 2026, with a potential PDUFA date in the third quarter [40][41]. Additional Insights - **Market Need**: Clene emphasizes the urgent need for ALS therapies, highlighting the devastating impact of the disease and the importance of early diagnosis and treatment [30]. - **Broader Applications**: While the focus is on ALS, Clene also has plans for multiple sclerosis (MS) treatments, indicating a broader pipeline potential [31][32]. - **Regulatory Flexibility**: The company is advocating for regulatory flexibility from the FDA, particularly for orphan diseases like ALS, which have limited treatment options [30][43]. This summary encapsulates the key points discussed during the Clene Inc. conference call, focusing on the company's strategic direction, product development, regulatory interactions, and financial health.

Summary of Cardiff Oncology FY Conference Call Company Overview - **Company**: Cardiff Oncology (NasdaqCM:CRDF) - **Lead Program**: Onvansertib, a highly selective PLK1 inhibitor targeting first-line RAS mutated metastatic colorectal cancer (mCRC) [2][3] Core Points and Arguments - **Market Opportunity**: The colorectal cancer market is significant, with approximately 150,000 new cases annually and over 55,000 expected deaths by 2027. The five-year survival rate for metastatic colorectal cancer remains low at 15% [7][8]. - **Unmet Need**: There are currently no approved drugs specifically for RAS mutated mCRC, highlighting a substantial unmet medical need [8][9]. - **Efficacy Data**: - Onvansertib demonstrated a confirmed overall response rate (ORR) of 72% when combined with FOLFIRI and bevacizumab, representing a 30% improvement over the standard of care [4][20]. - The median progression-free survival (PFS) has not yet been reached in the onvansertib arm, while the standard of care arm has a median PFS of approximately 11 months [21][22]. - The study showed favorable dose-dependent trends and PFS hazard ratios, indicating potential for practice-changing outcomes in underserved populations [5][22]. - **Regulatory Path**: The company plans to finalize a path to registration for onvansertib in frontline RAS-mutated mCRC after discussions with the FDA, aiming to provide a full plan within the first half of 2026 [6][27]. Competitive Landscape - **Current Treatments**: The standard of care for first-line mCRC has remained largely unchanged, primarily involving combinations of chemotherapy with bevacizumab [8][9]. - **Unique Positioning**: Onvansertib is positioned as the only program specifically designed for the entire RAS-mutated population, differentiating it from mutation-specific therapies currently in development [9][10]. Additional Insights - **Combination Potential**: Onvansertib shows promise not only in mCRC but also in other RAS-driven cancers, such as chronic myelomonocytic leukemia (CMML) [30][31]. - **Cash Position**: Cardiff Oncology reported $58.3 million in cash equivalents, sufficient to fund operations into the first quarter of 2027, although this does not include significant investments for the phase 3 study [33][34]. - **Clinical Benefit**: The company believes that the totality of data, including ORR, PFS, and hazard ratios, supports the clinical benefit of onvansertib, which is compelling for regulatory discussions [36][39]. Future Outlook - **Upcoming Milestones**: Cardiff Oncology plans to share more detailed data from the ongoing phase 2 study and regulatory feedback in the first half of 2026, with a focus on advancing to phase 3 trials [31][32][27].

Core Insights - Alkermes plc is a biopharmaceutical company focused on innovative medicines for central nervous system disorders, addiction, and cancer [1] Financial Performance - For the earnings report dated February 25, 2026, Alkermes reported an earnings per share (EPS) of $0.29, which was below the estimated $0.43 [2][5] - The company exceeded revenue expectations with reported revenue of $384.5 million compared to the anticipated $381.5 million [2][5] Valuation Metrics - Alkermes has a price-to-earnings (P/E) ratio of approximately 22.76, indicating how the market values its earnings [3][5] - The price-to-sales ratio is about 3.74, reflecting the market's valuation of its revenue [3] - The enterprise value to sales ratio is roughly 3.34, and the enterprise value to operating cash flow ratio is about 9.10, providing a broader view of the company's valuation [4] - The earnings yield for Alkermes is approximately 4.39%, indicating the earnings generated per dollar invested in the company's stock [4]

ImmunityBio Inc. (NASDAQ:IBRX) shares are down on Wednesday, cooling off from a huge up move as the company is reportedly experiencing significant revenue growth. This surge follows a strong performance driven by the sales of its lead drug, Anktiva, which has gained traction in the market.The stock has jumped over 50% over the last month, thanks to investor interest after preliminary earnings and several strategic partnerships.Anktiva Sales Surge: 750% Unit IncreaseImmunityBio reported a remarkable year-ove ...

Keros Therapeutics Conference Call Summary Company Overview - **Company**: Keros Therapeutics (NasdaqGM: KROS) - **Industry**: Biopharmaceuticals - **Focus**: Discovery, development, and commercialization of treatments for disorders linked to dysfunctional signaling of the TGF-beta superfamily of proteins, targeting pathways critical for blood cell growth, repair, and maintenance across various tissues [1][3] Core Products and Development - **Lead Candidate**: KER-065 (Rinvatercept) - **Indications**: Developed for neuromuscular diseases, specifically Duchenne muscular dystrophy (DMD) and amyotrophic lateral sclerosis (ALS) [2][4] - **Mechanism**: A modified activin receptor ligand trap designed to inhibit TGF-beta ligands, promoting muscle regeneration, increasing muscle size and strength, and reducing fibrosis and inflammation [5][11] - **Partnered Drug**: Elritercept - **Indications**: Developed for treating ineffective hematopoiesis in myelodysplastic syndromes (MDS) and myelofibrosis (MF) [2][21] - **Partnership**: Global license agreement with Takeda, including an upfront payment of $200 million and potential milestones exceeding $1.1 billion [21] Clinical Insights - **Duchenne Muscular Dystrophy (DMD)** - **Prevalence**: Approximately 1 in 3,500 male births [8] - **Current Treatments**: Glucocorticoids (short-term benefits), exon skippers (limited benefit), gene therapy (declining efficacy) [10] - **Potential of KER-065**: Increases muscle mass, decreases fat mass, improves bone mineral density, and reduces negative effects of glucocorticoids [11][14] - **Amyotrophic Lateral Sclerosis (ALS)** - **Patient Population**: Approximately 30,000 patients in the U.S. [16] - **Mechanism of Action**: Aims to preserve muscle function and quality of life by promoting muscle regeneration and potentially counteracting muscle atrophy [19] Financial Overview - **Current Financial Position**: As of the third quarter, Keros reported $383 million in cash, providing a runway into the first half of 2028 [24][25] - **Investment in Trials**: Funds allocated for phase 2 trials and advancing preclinical assets into clinical development [25] Upcoming Milestones - **DMD Trial**: Expected to start in the current quarter [24] - **ALS Trial**: Engagement with regulators planned for the second half of the year [24] - **Elritercept Phase 3 RENEW Trial**: Ongoing, with Takeda committed to starting frontline treatment in the 2025 fiscal year [26] Additional Insights - **Research and Development**: Keros has a proprietary library of modified activin receptor II ligand traps and is exploring a broad range of indications, including neurodegenerative diseases and obesity [22][23] - **Clinical Data**: Phase 1 study of KER-065 showed it was well tolerated with no serious adverse events, indicating a favorable safety profile compared to earlier molecules [13][14] This summary encapsulates the key points from the Keros Therapeutics conference call, highlighting the company's focus, product pipeline, clinical insights, financial status, and future milestones.

Key Takeaways Iovance reported a Q4 loss of 18 cents per share on $87M in revenues, topping estimates.IOVA's Amtagvi sales rose 33% to $65M, lifting gross margin to 50% after restructuring.IOVA shares jumped 31% on 50% ORR data in sarcoma and a new study plan.Iovance Biotherapeutics (IOVA) incurred a fourth-quarter 2025 loss of 18 cents per share, narrower than the Zacks Consensus Estimate of a loss of 22 cents. In the year-ago quarter, the company reported a loss per share of 26 cents.Total revenues for th ...

Key Takeaways RXRX reported a Q4 loss of 21 cents per share, beating estimates and narrowing from last year.Recursion revenues rose to $35.5M on a $30M Roche milestone payment and contributions from Sanofi.Recursion Pharmaceuticals ended 2025 with $753.9M in cash, funding operations into early 2028.Recursion Pharmaceuticals (RXRX) reported a loss of 21 cents per share in the fourth quarter of 2025, narrower than the Zacks Consensus Estimate of a loss of 28 cents. The company had incurred a loss of 53 cents ...